FIELD: medicine.
SUBSTANCE: invention relates to medicine, particularly to ophthalmology. Ophthalmic fused protein formulations of a VEGF-specific antagonist are suitable for intravitreal injections. The ophthalmic formulation has stable liquid ingredients and lyophilizable ingredients. The ophthalmic formulation contains a protein antagonist, has amino acids 27-457 of the sequence SEQ ID NO:4, an organic solvent, a tonicity agent, a sodium phosphate buffer, and additionally, a stabilising agent.
EFFECT: invention provides stability of the ophthalmic formulation.
11 cl, 8 tbl, 4 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| COMPOSITIONS OF ANTIBODIES | 2014 |
|
RU2694055C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
| ANTIBODY-CONTAINING COMPOSITIONS | 2009 |
|
RU2563179C2 |
| STABLE AQUEOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY COMPOSITION | 2016 |
|
RU2699544C2 |
| LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE | 2017 |
|
RU2741497C2 |
| STABLE COMPOSITIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN AND THEIR USE | 2014 |
|
RU2773172C2 |
| ANTIBODY-BASED FORMULATIONS | 2015 |
|
RU2704611C2 |
